Connect Biopharma Holdings Limited

CNTB • Biotechnology

$1.84

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$115.71M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.02Healthy liquidity · 3.74Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:23 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.84

Change0.00%

Shares Out62.88M

Market Cap$115.71M

Enterprise Value$84.82M

52W Range1.23 - 3.82

Beta-0.22

P/E-2.13

P/S155.10

P/B4.31

P/FCF-1.93

EV/Sales113.70

Price$1.84

Change0.00%

Shares Out62.88M

Market Cap$115.71M

Enterprise Value$84.82M

52W Range1.23 - 3.82

Beta-0.22

P/E-2.13

P/S155.10

P/B4.31

P/FCF-1.93

EV/Sales113.70

EV/EBITDA-1.52

EV/FCF-1.41

Earnings Yield-46.84%

FCF Yield-51.84%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-907.41%

Profit Margin-866.87%

Debt/Eq0.02

Current Ratio3.74

Quick Ratio3.74

Target$6.60

Target Upside258.70%

Target Median$7.00

Target Range4.00 - 8.00

Volume802.45K

Avg Volume370.07K

EPS Surprise-0.05

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

46/100

Why this score▼

Manageable debt level · 0.02Healthy liquidity · 3.74Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

CNTB

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$4.00

Mean

$6.40

Median

$7.00

High

$8.00

Company Overview

IPO: 3/19/2021

Industry: Biotechnology

P/B i: 4.31

Debt / Equity i: 0.02

Operating Margin: -90740.63%

Net Margin: -86687.50%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.02

Current Ratio: 3.74

Quick Ratio: 3.74

Status: Good

Insider Transactions

Recent executive and insider activity

LIU JEAN I

Transaction: 06/30/2026

BUY

Change

+6,718

Price

Not reported

Filing

07/01/2026

Type

BUY

Xanthopoulos Kleanthis Gabriel

Transaction: 06/30/2026

BUY

Change

+3,738

Price

Not reported

Filing

07/01/2026

Type

BUY

Huang James

Transaction: 05/29/2026

BUY

Change

+150,000

Price

$2.48

Filing

06/02/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
LIU JEAN I	BUY	+6,718	Not reported	06/30/2026	07/01/2026
Xanthopoulos Kleanthis Gabriel	BUY	+3,738	Not reported	06/30/2026	07/01/2026
Huang James	BUY	+150,000	$2.48	05/29/2026	06/02/2026
LIU JEAN I	BUY	+5,061	Not reported	03/31/2026	04/02/2026
Xanthopoulos Kleanthis Gabriel	BUY	+2,816	Not reported	03/31/2026	04/02/2026
Huang James	BUY	+1,160,000	$3.45	03/31/2026	04/01/2026
Huang James	OTHER	0	Not reported	03/18/2026	03/18/2026
LIU JEAN I	OTHER	+60,000	$2.50	03/16/2026	03/16/2026
Schoeneck James A	OTHER	+60,000	$2.50	03/16/2026	03/16/2026
WILSON KAREN J	OTHER	+60,000	$2.50	03/16/2026	03/16/2026
WILSON KAREN J	OTHER	0	Not reported	03/16/2026	03/16/2026
Xanthopoulos Kleanthis Gabriel	OTHER	+60,000	$2.50	03/16/2026	03/16/2026
Xanthopoulos Kleanthis Gabriel	OTHER	0	Not reported	03/16/2026	03/16/2026
Peraza Lisa	OTHER	+250,000	$2.69	03/16/2026	03/16/2026
Peraza Lisa	OTHER	0	Not reported	03/16/2026	03/16/2026
Quart Barry D	OTHER	+700,000	$2.69	03/16/2026	03/16/2026
Quart Barry D	OTHER	0	Not reported	03/16/2026	03/16/2026
Szekeres David Leslie	OTHER	+400,000	$2.69	03/16/2026	03/16/2026
Szekeres David Leslie	OTHER	0	Not reported	03/16/2026	03/16/2026

About the Company

Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Source - link

Peers

ARTV CNTX IFRX IMA KLRS MGX OVID QNCX STRO STTK

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C.

GlobeNewsWire

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and six months ended June 30, 2026, and provided a business update. “During the second quarter, we achieved important milestones with the completion of enrollment in both our Phase 2 Seabreeze STAT asthma and chronic obstructive pulmonary disease (COPD) studies.

GlobeNewsWire

Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month

Defense World

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.

Seeking Alpha

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, as an adjunct to standard of care for acute exacerbations in participants with asthma and type 2 inflammation. “Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of asthma,” said Barry Quart, Pharm.D.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-12	-0.29	-0.34	-0.05
2026-03-31	-0.3	-0.27	0.03
2025-08-13	-0.22	-0.23	-0.01
2025-03-31	-0.27	-0.05762	0.21238
2024-09-05	-0.02808	0.01895	0.04703
2024-04-16	-0.03201	-0.07416	-0.04215
2023-09-12	-6.92	-0.07667	6.84333
2023-04-11	-3.58	-0.15045	3.42955
2022-09-13	-5.28	-0.16199	5.11801
2022-03-31	-4.38	-0.16555	4.21445
2021-08-31	-2.36	-0.48004	1.87996